Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIVE-U Sub-study A: vepdegestrant plus abemaciclib in ER-positive/HER2-negative advanced or metastatic breast cancer
2022-502228-34-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Dec 2023
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of vepdegestrant and abemaciclib in breast cancer, sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities and Confirmed objective response. Planned start Dec 2023; status: authorised.
02
Drugs
vepdegestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-502228-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502228-34-00.